Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET. The company said the presentation will be webcast live and available for replay for a limited time.
Investors can find the webcast link on the Edgewise Events & Presentations page and are advised to connect several minutes early to ensure a timely connection.
Details
News Market Reaction – EWTX
On Mar 4, the day this news came out, EWTX closed 0.24% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Conference date
- March 11, 2026
- Leerink Global Healthcare Conference presentation date
- Presentation time
- 1:40 p.m. ET
- Scheduled start time of Leerink conference presentation
Historical Context
-
Planned MDA data presentations on sevasemten and related Becker MD analyses.
-
Inducement options for new employees under 2024 equity incentive plan.
-
Q4 and 2025 results with cash position and upcoming clinical catalysts.
-
Guggenheim biotech summit presentation with webcast access details.
-
Stock option grants to new employees under Nasdaq inducement rules.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html
SOURCE Edgewise Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.